Novavax’s COVID-19 Shot Finally Authorized In US, But Could Miss Out Again On Bivalent Booster
Still Hoping To Hit $4bn Revenues Despite Slow Start
Novavax will not catch up with Pfizer or Moderna, but the vaccine's EUA is nevertheless an inflection point for the company. • Source: Shutterstock 
